Headline: UNCAPTIONED: FDA Approves First-Ever Twice-Yearly HIV Prevention Shot
Caption:
FDA Approves First-Ever Twice-Yearly HIV Prevention Shot. In a major step forward for HIV prevention, the FDA has approved lenacapavir—branded as Yeztugo, the first HIV prevention shot that only needs to be taken twice a year. The injectable PrEP (pre-exposure prophylaxis) was proven to be highly effective in clinical trials, preventing nearly all HIV infections among participants. It's approved for adults and adolescents at risk of HIV, following a negative test. Unlike daily pills, lenacapavir offers a low-maintenance option that could help overcome barriers like access, stigma, and forgetfulness. But cost could be a hurdle: it's priced at over $28,000 per year in the U.S. Fortunately, Gilead has agreed to license the drug to generic manufacturers for 120 low-income countries to improve global access. Advocates call this a "game-changer" in the fight against HIV, but stress that equity—not just innovation—will determine its true impact.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT
Keywords: Health and Wellbeing,FDA,lenacapavir,Yeztugo,HIV prevention,twice-yearly injection,PrEP,clinical trials,adults,adolescents,HIV risk,daily pill alternative,low-maintenance,stigma,access,forgetfulness,cost,$28,000,Gilead,generic license,low-income countries,global access,game-changer,health equity
PersonInImage: